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INTRODUCTION
               The  importance  of  sun  light  has  been  recognized  since 
ancient  times.  Ultra  violet  light  is  a  small  component  of 
electromagnetic  spectrum with narrow band of  radiation from 200 – 
400nm. 
The ultra violet spectrum is further divided into
 Ultra violet C (200-280nm), 
 Ultra violet B (280-315 nm) and 
 Ultra violet A (315-400 nm). 
Artificial  UV radiation  that  allows  precise  dosing  has  only  been 
available for the last century.    
The  phototherapy  is  a  well  understood,  time  proven  method 
for  achieving  remission  in  majority  of  cases.  It  is  a  relatively 
safe method for treatment of :-
 Psoriasis poorly responsible topical treatment 
 Rapidly spreading psoriasis, 
 Wide spread psoriasis (over 20 % of body surface)
 Severe psoriasis of palms and soles.
REVIEW OF LITERATURE
PSORIASIS
Psoriasis  is  a  chronic,  recurrent  erythemato  squamous 
disorder  involving the  skin,  nail,  joint  and mucous  membrane.  Its  a 
non-  contagious  disease  affecting  two  percent  of  the  world’s 
population.
 Hippocrates  provided  detailed  description  of  many  skin 
disorders that have dry and scaly eruptions which probably includes 
psoriasis and leprosy under the name “lopoi” (meaning epidermis).
The  two  conditions  were  also  grouped  together  in  the  old 
testament  with  the  result  then  many  psoriatics  were  rejected  by  the 
community,  the  church  declared  them  officially  dead  and  in  1313 
Philip,  the  fair  ever  ordered  them to  be  burned  at  the  stake.  It  was 
not  until  19 t h  century  that  psoriasis  was  recognized  as  an  entity 
apart from leprosy.
Robert  Willan  was  first  to  give  an  accurate  description  of 
psoriasis  although  Hebra  and  Kaposi  (1876)  definitely  separated  a 
clinical picture of psoriasis from that of Leprosy.
Galen first introduce the name “psoriasis”. 
With  in  the  spectrum  of  cutaneous  manifestations,  different 
expression  like  chronic  plaque  type,  pustular  type,  guttate  type, 
erythrodermic, inverse type etc., are seen. 
The  cause  of  psoriasis  is  related  to  the  immune  system  and 
more specifically T lymphocytes,  which is  triggered by non specific 
antigens.
The  over  active  T  cells  trigger  other  immune  response  that 
cause  an  increase  production  of  epidermal  cells  which  results  in 
reduction in the cell transit time from basal layer to corneal layer.
The  aim  of  psoriasis  treatment  is  to  interrupt  the  cycle  that 
causes  increased  epidermal  turn  over,  there  by  reducing  the 
inflammation & plaque formation.
Psoriasis treatment can be divided into 3 main types.
 Topical therapy
 Phototherapy
 Systemic therapy
           Topical  therapy  is  mainly  used  to  treat  the  psoriasis 
involving limited area. For larger area of involvement, phototherapy 
is  the  preferred  treatment,  as  the  systemic  therapy  like 
methotrexate,  retinoids,  cyclosporine  etc.,  are  not  without  much 
side effects. 
PHOTOTHERAPY
As  the  name  suggests,  phototherapy  uses  natural  or  artificial 
light.  The  simplest  and  easiest  form  of  phototherapy  involves,  
exposing the skin to controlled mount of natural sunlight. 
 HISTORICAL ASPECTS
 The  first  report  of  use  of  phototherapy  in  the   treatment  of 
skin  disorders  dates  from  1400  BC  from  India  when  patients 
with  vitiligo  were  given  certain  plant  extracts  (whose  active 
ingredients include psoralens) and then exposed to sunlight.
 Ancient  Egyptians  also  recognized  the  beneficial  effect  of 
sunlight. 
 In 1672,  Newton discovered the spectrum of visible light.
 UV light was first discovered in early 1700s.
  In  1890,  Modern  phototherapy  began  when  Niel  Finsen,  the 
father  of  modern ultraviolet  therapy,  used a  carbon arc  source 
to  treat  Lupus  vulgaris.  He  was  awarded  the  Nobel  Prize  in 
1903.
 In  1923,  Goeckerman,  at  Mayo clinic,  introduced his  regimen 
(artificial broad band UVB + coal tar.) 
 In  1947,  Fahmy,  an  Egyptian  pharmacologist,  isolated 
psoralen compounds from ammi majus.
  In  1953  Ingram  introduced  his  regimen  combining   artificial 
broad band UVB, coal tar and dithranol.
 In landmark of development,  in 1974 Parrish et al reported the 
useful  role  of  high  intensity  UVA  using  newly  developed 
Henselar  high  intensity  artificial  UVA  light  in  combination 
with  oral  psoralen  in  the  treatment  of  psoriasis  leading  to 
advent of PUVA therapy.
 In  1978,  Wiskemann   introduced  broad  band  UVB  tubes   for 
the  treatment  of  psoriasis  and  uremic  pruritus. 1 Broad  band 
UVB was  as  effective  as  PUVA in  the  treatment  of  psoriasis.  
Potential  carcinogenic  effect  of  broad  band  UVB made  it  less 
popular.
 The  break  through  came  after  1988,  when  narrow  band  UVB 
phototherapy was  introduced for  the  treatment  of  psoriasis  by 
van Weelden et al and Green et al 2 , 3 .
NARROW BAND UVB PHOTOTHERAPY
UVB  rays  constitute  5  –  10  %  of  ultra  violet  light  reaching 
earth. The range from 280 -320 nm.
THERAPEUTIC SPECTRUM
Phillips  TL-01 Fluorescent  Lamps  emits  narrow band  UVB in 
the range of 310 – 315 nm, with peak at 312 nm.
*   It has a relatively narrow spectrum of emission compared to
    broad band UVB.
*   Has a  reduction in the Erythmogenic wave length (290 – 305
    nm range),
*   5 – 6 times increased emission of longer UVB wave length, there
     by resulting in a higher phototherapy index for psoriasis.
PRINCIPLE AND MECHANISM
The  mechanism  of  action 4  of  narrow  band  UVB phototherapy 
has not been completely understood.
 The  major  molecular  target  for  UVB  is  nuclear  DNA,  with 
absorption  by  neucleotides  leading  to  induction  of  various 
DNA photoproducts, notably pyramidine dimers.
 the inhibitory action on DNA synthesis. 5
 Induction  of  T-Lymphocyte  apoptosis  –therapeutic   effect  in 
psoriasis, eczema, CTCL etc. 6
 Other mechanisms:
-    Effects on cell cycle 7
-    Antimicrobial effect and alteration of skin flora. 8
     -    Induction of anti inflammatory and immunosuppressive
 cytokines 9 , 1 0 ,1 1  - production of IL -10, reduced natural killer
 cell activity and lympho proliferation.
     -   It also induces isomerisation of urocanic acid from “trans” to 
         “cis” form, which may be important in the immuno
         modulatory effects. 1 2
     -  Thus narrow band UVB has therapeutic action in different
        diseases states involves a combination of effects including
       changes in cell cycle kinetics, alteration in cytokine expression 
       and immunomodulation.
 
SOURCE OF NB - UVB
The source of NB-UVB is whole body phototherapy unit is with
– Philips TL-01 fluorescent bulbs (100W)
– Sylvania UV-21 
It delivers UVB in a range of 310 – 315 nm with a peak at 312 
nm.  Its  in  a  reduction  in  erythmogenic  wavelength  in  the  290  – 
305nm.
         NB-UVB  cabins  available  commercially  either  incorporate 
TL-01  alone  or  in  combination  with  UVA  tubes.  Combination 
chambers takes a longer time to administer a treatment dose.
.        Recently  shorter  tubes  of  NB-UVB is  also  available  in  small 
area  treatment  equipments  (hand  and  foot  unit,  NB-UVB comb)  for 
the therapy of localised body area.
Targeted  UVB  phototherapy  is  delivered  via  a  portable  unit 
with  UV exposure  limited  to  the  affected  area  like  psoriatic  plaque 
or vitiliginous macules. 
DOSING SCHEDULE
NB-UVB  therapy  schedule  can  be  tailored  according  to  the 
patients skin type and local experience.
There  are  two  regimens  that  are  commonly  used  to  determine 
the initial dose.
1.  Involves  determination  of  individuals  minimum  erythema  dose 
(MED) by means of separate band of TL-01 tubes.
 MED is determined 1 3 by standard method.
 A  template  with  20  apertures  (10  on  each  side)  of  1.5  X  1.5 
cm2  is  made  over  the  back  of  a  cotton  suit  used  by  operation 
theatre staff.  The cotton flaps made  over the apertures enable 
to either shut or keep the apertures open by using Velcro.  The 
source of  NB-UVB is  whole    body phototherapy unit  with 24 
Philips TL-01 bulbs.
 To  determine  MED  a  single  panel  in  whole  body  unit  with  6 
bulbs is used.
 All  apertures  are  kept  open and back –  irradiated   with  50mJ 
of  NB-UVB.  One  aperture  is  closed  and  remaining  aperture 
are closed one after  the  other  after  delivering 50mJ more than 
the  previous  aperture.  The  dosing  schedule  of  NB-UVB  (in 
mJ) is 50, 100, 150,200,250,300,350,400,450, 500.
 The  reading  were  taken  24  hours  after  exposure.  For  311  nm 
therapy, the initial dose should be 70% MED.
 MED should be determined before  NB-UVB for  all  conditions 
except vitiligo
 Patients  are  treated 3-5 times a  week.,  Although more sittings 
will  be  beneficial,  2-3  sittings  are  more  cost  effective  and 
hence more acceptable.
 If  initial  dose  is  tolerated  40,20,  or  10% incremental  increase 
of previous dose is used. When a previous treatment results  in 
erythema,  no  treatment  is  given  in  next  schedule.  Increment 
every  second  and  third  sittings  is  effective  possibly  because 
sub-erythemogenic  dose  of  UVB  is  also  effective  as 
erythemogenic dose. 
2. Another approach, involves a standard starting dose
(280mJ  /  cm 2)  with  stepwise  increase  (usually  20%) 
depending upon the patients erythema response.
 In  case  of  mild  erythema,  the  irradiation  dose  is  held 
constant  for  subsequent  treatment  are  until  resolution  of 
symptoms. 
 The  goal  of  the  therapy  is  to  achieve  persistent 
asymptomatic  erythema.   In  case  of  painful  erythema  with 
or without edema /  blistering,  further treatment is withheld 
till  the  symptoms  subside.  After  resolution  of  over  dose 
symptoms,  the  dose  administered  is  50%  of  the  last  dose 
and subsequent increments should be by 10%.
MAXIMUM DOSE 1 4
In  responsive  patients  NB-UVB  can  be  given  for  a  maximum 
of  24  months.  After  one  year,  a  resting  period  of  3  months  is 
recommended  to  minimise  the  annual  cumulative  dose  of  UVB.  In 
children, the maximum duration allowed is 12 months.
INDICATIONS
 Psoriasis 
 Generalized vitiligo
 Atopic dermatitis 
 Lichen planus
 Chronic urticaria 1 5
 Seborrhoeic dermatitis 
 Prophylactic  low  dose  NB-UVB  is  beneficial  for 
photosensitive dermatoses like polymorphic light eruption, 
actinic  prurigo,  hydroa  vacciniforme,  cutaneous 
porphyrias  by  providing  “hardening  photo  protective” 
effect.  A typical  course  involves  10-15 treatment  given in 
early spring. 1 5
 Beneficial  role  has  been  observed  with  airborne  contact 
dermatitis 1 6 , 1 7 ,1 8  to  parthenium hysterophorus,  a  frustrating 
problem for  both the patient and the physician.
LONG TERM USE AND ADVERSE EFFECTS
Acute:
 Immediate sun burn
 Erythema 1 9 
 Lesional blistering of Psoriatic plaques. 2 0 ,2 1
 Pruritus 2 2  
 Corneal burn 2 3  if eyes are unprotected 
 Reactivation of Herpes simplex virus 2 4
 Photoallergic dermatitis 
Chronic
 Freckling of the skin
 Photo  degenerative  changes-reduced  dermal 
hydroxyproline  levels  and  induction  of  gelatinases  and 
elastin cross-links have been shown.
 Possible  increase  of  skin  cancer.-  It  has  been calculated 
that  the  long  term  risk  of  carcinogenesis  with  its  use 
may be less than that of PUVA therapy 2 5 .  
.
COMBINATION THERAPY
NB-UVB  Phototherapy  may  be  combined  with  topical  and 
systemic  agents  to  achieve  higher  clearance  rates,  longer  disease 
free intervals and lower carcinogenic risk.
 UVB with  Calcipotriol  –  increases  the  therapeutic  efficacy  of 
phototherapy and reduces the irritation caused by calcipotriol. 
 UVB  with  topical  tazarotene  gel  –  promotes  more  effective, 
faster  clearing  of  psoriasis  when  compared  to  either  type  of 
phototherapy  alone.  Pre-treatment  with  tazarotene  gel  for  2 
weeks  before  phototherapy  significantly  reduces  the  mean 
minimal erythema dose for UVB. 
 Salt water bath (Balmotherapy)
 UVB with glucocorticoids
 UVB with Systemic retinoids - Combining retinoids with UVB 
theoretically reduces the risk of carcinogenic effect of UVB. 
 Topical emollient application – alters the optical properties of 
psoriatic  lesions,  improve  transmission  of  UVB  and  lead  to 
increase efficacy. 
 Combination  regimens  of  UVB  therapy  with  methotrexate  or 
cyclosporine  A  are  not  advisable,  because  both  substances 
increases the possibility of UV induced skin tumors. 
PUVA therapy
Psoralens:
Psoralens  are  clinical  compounds  derived  from  certain  plants 
such  as  ammi  majus  found  in  Egypt  and  Indian  plants  babachee 
which is also called as psoralea corylifolia. 
Psoralens has been found in more than 30 plants such as Lime, 
Lemon, Bergamot, parsley, celery, fig, cloves 2 6 etc.
The  most  widely  used  psoralen  which  is  tricyclic 
furocoumarin  is  8-methoxypsoralen  (8-MOP,  methoxypsoralen, 
xanthotoxin) – principally of plant origin.
Synthetic form of Psoralen :
- 4,5,8 –Trimethyl Psoralen (TMP,trioxsalen)
- 5  Methoxy  psoralen  (bergapten,  3-carbethoxypsoralen  and 
angelicin) 
Pharmacology :
When  taken  by  mouth  methoxsalen  (8-MOP)  is  absorbed  by 
gastro  intestinal  tract.  Increased  photo  sensitivity  is  observed  one 
hour  after  the  dose,  reaches  a  peak at  about  2  hours  and disappears 
after about 8 hours. 2 7
The  absorption  of  8-MOP  is  increased  by  concomitant  food 
ingestion as well as by differences in drug formulation.
It  is  metabolised  in  liver  by  hydroxylation  and  glucuronide 
formation and over 90% excreted in urine within 12 hours. 2 8
Methoxsalen  has  a  serum  half  life  of  approximately  1  hour 
and  rapidly  eliminated  which  prevents  photosensitivity 2 9.  When 
applied  locally  8-MOP  rapidly  penetrates  the  skin  and  can  be 
detected in the urine after 4 hours. 3 0
Psoralen Photochemistry : 3 1
The  major  photochemical  reaction  contributing  to  the  cellular 
damage,  is  the  formation  of  monofunctional  and  bifunctional 
adducts  of  psoralen  with  pyrimidine  bases  in  the  DNA.  This  is 
mediated by intercalation of psoralen with DNA base pair.
Mechanism of Action :
 The  formation  of  mono  /  bifunctional  adducts  results  in 
immediate  inhibition  of  DNA  synthesis  and  cell 
proliferation.
 Immunological  alteration  by  affecting  specific  cells  like 
lymphocytes or polymorpho nuclear leucocytes. 
 Decrease  in  the  percentage  of  T  –  lymphocytes 3 1 ,3 2 
following PUVA therapy has been reported :
 Selective  cytotoxicity  through  production  of  free 
radicals.
 Stimulation of melanogenesis. 3 1 , 3 3                        
Sources of UVA Radiation :
The commonly used sources of UVA are,
• Fluorescent PUVA
• High pressure metal halide lamps
    Fluorescent PUVA lamp has emission peak at  352nm although 
the  spectrum  of  anti-psoriatic  activity  and  phototoxic  erythema 
peaks  at  335nm,  long  wavelength  has  proved  equally  effective  for 
clearing psoriasis    
Indications 
Diseases treatable by PUVA therapy are,
 Alopecia areata 3 7
 Atopic dermatitis 4 0  
 Cutaneous T-cell lymphoma 
 Dyshidrotic eczema
 Eosinophilic  folliculitis  and  other  pruritic  eruptions  of  HIV 
infections.
 Graft Vs Host Disease
 Generalised Granuloma annulare 3 4 , 3 5
 Generalised Lichen planus. 3 5 ,3 6
 Localised scleroderma    
 Palmoplantar pustulosis
 Parapsoriasis 
 Pityriasis lichenoides
 Photodermatoses 
 Polymorphic light eruption 
 Pityriasis rubra pilaris 
 Psoriasis 
 Seborrhoeic dermatitis 3 9
 Urticaria pigmentosa
 Vitiligo  
Methods of Treatment :
         8-methoxypsoralen  in  the  dose  of  0.6  to  0.8  mg  /  kg  body  
weight  is  administered  orally  followed  by  whole  body  irradiation 
after  1  to  3  hours.  The  initial  dose  of  UVA  is  predetermined  by 
either skin typing or by determining minimal phototoxic dose.
Initiation of PUVA therapy according to the skin photo type, 4 1  
Skin Phototype      Recommended Dose(J/cm 2)
I. Always burn, never tan 0.5
II. Always burn, sometimes tan 1.0
III. Sometimes burn, always tan. 1.5
IV. Never burn, always tan 2.0
V. Moderately pigmented 2.5
VI. Black 3.0
Type I to IV determined by history,  Type V & VI are determined 
by physical examination.  
Minimal Phototoxic Dose 4 2 ,4 3 , 4 4 , 4 5  
MPD  is  defined  as  minimal  dose  of  UVA  that  produces  a 
barely perceptible but well defined erythema when template areas of 
skin  are  exposed  to  increasing  dose  of  UVA  ranging  from  0.5  to  5 
J/cm2 
After  1  to  2  hours  of  administration  of  oral  psoralen,  a 
template is  placed on the patient’s  buttock as in the area of  greatest  
UV  sensitivity.  Template  consists  of  6  to  8  areas  of  at  least  1  cm 2 
which can be exposed to increasing dose of UVA. Erythema reading 
is  performed 72 hours  after  testing,  at  which psoralen phototoxicity 
reaction usually reaches its  peak.  A fraction of its dose, example 50 
–  80%  is  frequently  used  as  a  starting  dose  in  PUVA  therapy 
although  MPD is  more  time  consuming  than  phototyping,  it  allows 
for more accurate and higher UVA doses during initial treatment.
Protocol for PUVA Therapy :
Various  protocols  of  oral  PUVA  therapy  have  evolved  as 
follows,
United States Protocol :
1. First treatment exposure dose is based on skin typing.
2. patients are treated twice or thrice a week.
3. Dose  increment  –  0.5  to  1.5  J  /  cm 2 depending  on  the 
therapeutic response.
European Protocol :
1. First  Treatment  is  administered  after  determination  of 
individual’s  MPD  and  the  initial  UVA  dose  is  the  patients 
MPD.
2. Four Treatments are given / week.
3. Two treatments are given consecutive days followed by a rest 
on day 3 after which treatment is resumed for 2 days.
4. Dose increments are individualised.
Manipal Protocol :
1. The usual starting dose is 4 to 6 J / cm 2
2. Dose  increments  of  0.5  J  /cm 2  are  done  each  time  till  a 
maximum of 18 J /cm 2  is reached.
3. Treatment is given thrice or 4 times in a week.
 Contraindications for PUVA therapy :
Absolute Contraindication  :
1. Pregnancy or in patients  trying to conceive 
2. Xeroderma pigmentosum.
3. Lupus erythematosus
4. Severe hepatic or renal failure 
Relative Contraindication :
1. Personal or family history of melanoma  
2. Immuno suppressed patients.
3. Previous exposure to carcinogen such as X-Rays, arsenic etc.,
4. Outdoor workers in relatively sunny areas
5. Children and Young adults 
6. Minimal diseases 
7. Light skin and fair or red hair 
8. Received over 200 PUVA treatment 
Protective Measures with PUVA Therapy
During Treatment :
1. Patient  should  wear  specially  designed  goggles  to  protect 
their eyes from UVA radiation.
2. Male genitals 5 3  must be covered throughout the process.
After Treatment :
1. Patient  should  wear  UVA  absorbing  wrap-around  sun  glasses 
for atleast 12 hours after treatment.
2. Patient  should  avoid  sun  exposure  to  day  light  for  atleast  8 
hours  after  taking  the  drug.  Otherwise  should  wear  heavy 
opaque clothing or apply sunblock with SPF of more than 15
Acute Side effects
Side effects oral psoralen :
1.  Nausea and vomiting 
2.   Hepatic 5 4 , 5 5  /  Renal 5 6 Effects  :  no laboratory  or  HPE evidence 
of hepatotoxicity / renal toxicity after several years of follow up
Acute Side effects of PUVA :
1. Increased  delayed  erythema  reaction  to  severe  burns  with 
blistering.
2. persistent pruritus.
3. Stinging pain
4. Polymorphous light eruption like rashes 
5. Acne like eruption 
6. Subungual haemorrhage
7. Hypertrichosis        
8. Exacerbation of SLE
9. Exacerbation of bullous pemphigoid 
Potential long term risk of PUVA :
1. Chronic Actinic damage
• Photoageing
• Actinic Keratoses
• Generalised PUVA lentiginosis
    2.Carcinogenesis 66
• Its  the  major  concern  about  long  term  and  repeated  PUVA 
treatment associated with high UVA dose.
• Due  to  DNA  damage,  there  is  down  regulation  of  immune 
response.
• In  PUVA  patients,  risk  of  squamous  cell  carcinoma  but  not 
the  basal  cell  carcinoma is  significantly increased and is  dose 
dependent.
• Only  a  few  anecdotal  cases  of  malignant  melanoma  has  been 
observed  in  long  term  PUVA  treated  psoriatics  and  no 
increased  risk  of  melanoma  was  found  in  all  large-scale 
studies
• Risk was greater in patients exposed to higher doses of PUVA 
and   in  patients  exposed  previously  to  other  carcinogens  like 
ionizing  radiation,  UVB  therapy,  methotrexate,  tar,  arsenic 
and appeared to be increasing with passage of time.
• Risk  of  both  melanoma  and  squamous  cell  carcinoma  in 
PUVA  should  weighed  against  substantial  efficacy  of  PUVA 
and risk of other therapies.
3. Ophthalmic Effects 57  
• Despite  data  from  animal  models,  which  indicate  a  risk  of 
premature  cataract  formation,  clinical  evaluation  shows  no 
increase  in  lens  opacities,  even  in  patients  who  neglected 
careful eye protection.
• Majority  of  prospective  studies  did  not  report  an  increased 
incidence of lens opacities in patients who used eye protection 
following psoralen ingestion
Other forms of PUVA Therapy :
1. Solar Irradiation : 
In  this  method 8 MOP is  given orally  in  conjugation with  sun 
light  exposure  (PUVASOL).  A  major  disadvantage  in  PUVASOL 
therapy is difficulty in quantifying UV light.
2. Topical Treatment :
 Topical  application  of  psoralen  followed  by  UVA irradiation 
is  given.  0.01%  TMP 4 6  is  given  10  –  20  minutes  prior  to  UVA 
exposure  is  convenient  for  topical  application 4 7 because  of  its  weak 
penetrability. 
Advantage  of  this  therapy  systemic  side  effects 4 9 of  psoralen 
is avoided but limitation are :
1. Application  to  each  lesion  is  laborious  and  time 
consuming.
2. Formation  of  erythema  and  blistering  is  more 
common with topical psoralen application.
3. Intense  irregular  pigmentation  may  been  seen  at 
the site of treated plaque.
3. Bath PUVA : 
Bath  solution  are  prepared  by  diluting  50ml  of  8-MOP  in 
100L of bath water. 5 0
Patients  soak for  15 minutes  in  this  solution and then  quickly 
wipe  dry.  Immediately  patients  are  given  whole  body  irradiation 
with UVA.
8-MOP required smaller amount of UVA radiation and yielded 
fewer side effects. 5 1
4. Bath suit PUVA 5 2
Advantage of Bath suit delivery of 8- MOP are 
 Required only 2L of water and 0.8 ml of 8-MOP solution.
 This  treatment  can  be  carried  out  at  home  with  sun  light 
as UVA source (PUVASOL)
 Irregular  pigmentation  seen  with  topical  PUVA  has  been 
overcome. 
Combination Therapy
PUVA therapy can be combined with 
1. Acitretin 
2. Methotrexate 
3. Tazarotene  Gel
4. In combination with UVB 
   Combination  therapy  helps  in  lowering  the  dose  of  radiation 
and  minimizing  the  side  effects.  In  addition,  retinoids  help  protect 
against  skin  cancer,  while  methotrexate  may  increase  the  risk. 
Calcipotriol  should  not  be  combined  since  UVA radiation  degrades 
vitamin D3.
AIM OF THE STUDY
   This  study  is  conducted  in  patients  with  chronic  plaque 
type psoriasis, 
 To  evaluate  the  efficacy,  side  effects  and  cumulative 
dose of Narrow Band UVB Phototherapy.
 To  evaluate  the  efficacy,  side  effects  and  cumulative 
dose of  PUVA phototherapy.
MATERIALS AND METHODS
The  material  for  this  study  was  from  the  patients  with 
chronic  plaque  type  psoriasis,  attending  the  skin  OPD,  Government 
Rajaji  Hospital,  Madurai  Medical  College,  Madurai,  during  June 
2007 – May 2008.
The diagnosis of Psoriasis was made on clinical grounds
INCLUSION CRITERIA:
Patients  with  chronic  plaque  type  psoriasis  involving  greater 
than 20% of the body surface area.  
EXCLUSION CRITERIA: 
For NB-UVB Group:
 Photosensitive disorders 
 Previous History or family history of malignant melanoma
 History of skin cancers or photodamage 
 History of exposure to inorganic arsenic or ionising radiation 
   
 For PUVA Group:
 Age less than 18 years
 Pregnant and lactating women
 Photosensitive disorders 
 Previous History or family history of malignant melanoma
 History of skin cancers or photodamage 
 History of exposure to inorganic arsenic or ionising radiation 
 Significant hepatic, renal or cardiac dysfunction
 Chronic alcoholics
 Active infections like tuberculosis
 Cataract
All  patients  were  explained about  the  disease  and the  benefits 
and side effects of therapy were discussed with them.
Consent  was  obtained  from  all  patients  before  initiation  of 
therapy.
All patients were evaluated as follows
1. History
2. General Examination
3. Systemic examination
4. Dermatological examination
5. Investigations
a. Complete haemogram
b. Urine analysis
c. Blood  sugar,  urea,  serum  creatinine,  calcium 
and 
uric acid
d. Liver function tests
e. Blood VDRL
f. ELISA for HIV
g. Ophthalmic evaluation
h. X – ray chest
TREATMENT PROTOCOL AND METHODOLOGY :
     The study population was divided into 2 groups-Group A and B.
Group A  :  Narrow Band UVB phototherapy
Group B  :  PUVA therapy.
PROTOCOLS: 
Group A : (NB – UVB)
 20 patients were included in this study.
 All patients were asked to wear UV goggles when inside 
the phototherapy unit.
 Men were advised to wear genital protection.
 Patients  were  asked  to  apply  mineral  oil  on  the  plaques 
of psoriasis prior to the exposure of UV light.
 Irradiance  of  UVB  light  were  recorded  on  a  once  a 
month basis  using the standard method of manufacturers 
of phototherapy unit.
 Initial  UVB  dose(mJ/cm 2)  were  calculated  according  to 
the skin phototype of the patient.
 The  manual  method  for  calculation  of  time  (seconds)  to 
set  UVB  control  panel  to  deliver  the  dose  is  by  the 
following equation,
        Time (Seconds) = Dose (mJ/cm 2) / irradiance    (mw/cm 2)
 Patients  were  advised  to  stand  in  the  centre  of  the 
phototherapy unit with their arms rest.
 Patients  are  instructed  to  come  out  of  the  chamber 
when  the  light  go  out  or  if  they  became  uncomfortable 
during  the  treatment  either  from  burning  or  stinging 
sensation of the skin.
 Subsequent  dose  increments  were  made  at  every  third 
sitting at an increment 50 mJ/cm 2  of the previous dose. 
 Treatment were given thrice weekly.
 Every patient were monitored regularly after six to eight 
sittings.
GROUP B (PUVA)
 20 patients were included in this group. 
 Oral  8-methoxy  psoralen  crystalline  tablets  at  a  dose  of 
0.6mg/kg rounded up to the nearest of 20mg were given.
 After  2  hrs  of  oral  8-MOP,  they  were  exposed  to  UVA 
radiation in the UVA cabinet. 
 The  starting  UVA  dose  were  determined  by  skin  type. 
Treatment was given twice weekly. 
 Patients  were  asked  to  wear  UV  blocking  sunglasses 
during  exposure  in  the  cabinet  and  also  for  24  hrs  after 
treatment. 
 Men wore genital protection inside the cabinet.
 UVA  irradiance  of  the  cabinet  was  measured  monthly 
using UVA radiometer. 
 Exposure  time  in  seconds  was  calculated  using  the 
formula
                 Time in (sec) = Required dosage (Joules/cm   2   ) x 1000
    Irradiance (mw/cm 2)
 In  our  study,  all  patients  belonged  to  skin  phototype  IV 
& V and were started with 3 J/cm 2.
  Subsequent  increments  of  0.5/cm 2  were  given  based  on 
response  to  therapy  and  presence  or  absence  of 
erythema.
Follow up
 Patients  were  followed up every  week until  cessation of 
treatment.
 Complete  haemogram  was  done  every  2  weeks  for  the 
first month and therefore once a month.
 Liver  function  tests,  blood  urea  and  serum  creatinine 
were done every month.
 Adverse  effects  reported by the patients  or  noticed were 
recorded.
Efficacy Assessment
Severity  and  extent  of  psoriasis  were  evaluated  using 
“Psoriasis Area and Severity Index” (PASI).
        Severity  of  Erythema  (E),  Desquamation  (D)  and  Induration 
(I) was recorded on a 5 point scale as follows:
0 - Nil
1 - Mild
2 - Moderate 
3 - Severe
4 - Very Severe
The area of involvement was recorded on a 7 point scale as follows:
0 - Nil
1 - < 10 %
2 - 10 % - 29 %
3 - 30 % - 49 %
4 - 50 % - 69 %
5 - 70 % - 89 %
6 - 90 % - 100 %
PASI was calculated as follows
PASI = 0.1 ( EH  + IH  + DH  ) AH  + 0.2 (EU  + IU  + DU)AU  +
0.3 ( ET  + IT  + DT  ) AT  + 0.4 (EL  + IL  + DL)AL   
A - Area
H - Head
U - Upper Limb
T - Trunk
L - Lower Limb
OBSERVATION AND RESULTS
1).     Age Distribution:
 The range of age was from
• 12 – 70 yrs for group A and
• 31 to 60 yrs in group B                                    
 Mean age in our study was
 Group  A (NB-UVB): 40.7yrs, Group B(PUVA) : 44.05 yrs
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2) Sex Distribution :   
Males out numbered females in both groups.
Sex
GROUP A
(NB-UVB)
GROUP B
(PUVA)
No. % No. %
Males 17 85 18 90
Females 3 15 2 10
3) Duration of Illness :
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Males Females
     The  range  of  duration  of  illness  was  from 3  months  to  15 
years and mean was as follows,
Group A : 3.9     (UVB)
Group B :   3.92   (PUVA)
Duration of 
illness
(in months)
GROUP A
(NB-UVB)
GROUP B
(PUVA)
No. % No. %
Upto 12 months 7 35 7 35
13-36 months 3 15 6 30
37- 60 months 5 25 2 10
61-120 months 5 25 3 15
> 120 months - - 2 10
4) Family History :
DURATION OF ILLNESS
35
15
25 25
0
35
30
10
15
10
0
5
10
15
20
25
30
35
40
Upto 12
months
13-36
months
37- 60
months
61-120
months
> 120
months
P
E
R
C
E
N
T
A
G
E
GROUP A - NB-UVB GROUP B - PUVA
     Family history was not present in any of the patients in 
our study.
Family History
Group  A 
(NB-UVB )
Group  B
(PUVA) 
No. % No. %
Yes - - - -
No 20 100 20 100
5) Joint Involvement:
Five patients in our study had joint involvement. 
  -   3 patients had symmetrical poly arthritis,
 -    2 patients had peripheral asymmetrical oligo arthritis.
6) Nail Changes :
Totally 17 pts (42.5%) have nail involvement, out of which
 16 pts (40%)  had nail pitting.
 8 pts (20%)  had onycholysis.
 4 pts (10%) had Subungual hyperkeratosis.
 1 pt (5%)  had yellow discolouration.
     Some cases had more than one changes.
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7)  PASI Reduction
Group A
Mean PASI score at 0,4, 8,12 and16 weeks have been 
tabulated and its reduction is depicted in (Graph No.1 )
No. of weeks
Mean   PASI   Score
Group A                    Group B
(NB-UVB)                      (PUVA)
0 week
4 t h  week
8 t h  week
12 t h  week
16 t h  week
35.0
22.5
12.5
7.3
1.3
31.0
25.1
15.3
8.4
2.9
PASI REDUCTION  :   GRAPH - I 
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8)  Percentage reduction in PASI :
WEEKS
GROUP A
(NB – UVB)
GROUP B
(PUVA)
4 t h  week
8 t h  week
12 t h  week
16 t h  week
32.2%
62.4%
78%
96.7%
19%
50.7%
73%
90%
    Graph II. depicts the percentage reduction in PASI scores in both 
groups at 4,8,12 and 16 weeks.
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 From  the  table  of  PASI  reduction  we  can  see  that  the  mean 
base  line  PASI  scores  in  both  group  are  35.0  in  group  A  and 
31.0  in group B respectively.
 From the  graph I  –  group  A shows  gradual  reduction  in  PASI 
with  a  mean  PASI  score  of  22.5  at  4  weeks,  12.5  at  8  weeks,  
7.3  at  12  weeks  and  1.3  at  16  weeks.  These  values 
corresponds  to  the  percentage  reduction  of  32.2%,  62.4%, 
78%,  96.7%  at  the  end  of  4,8,12  and  16  weeks  respectively 
which is shown in graph II.
 In  group  B,  the  PASI  score  of  25.1,  15.3,  8.4,  and  2.9  at  the 
end  of  4,8,12  and  16  weeks  which  corresponds  to  the 
percentage  reduction  of  19%,  50.7%,  73%  and  90.0%  at  the 
end of 4,8,12 and 16 weeks respectively.
9) Mean cumulative UVB Dose and UVA Dose.
GP – A
(NB – UVB)
GP – B
PUVA
Average No. of 
Exposure
36.06 30.9
Duration of 
treatment (weeks)
11.8 14.9
Mean cumulative 
Dose  (J / cm 2) 
27.2 223.3
The mean cumulative dose,  average no.  of  exposures and total 
duration of treatment of UVB, & UVA has been tabulated.
10) Response  to Therapy :
Based  on  the  percentage  of  PASI  the  results  were  graded  as 
good (75- 100%), moderate (50-75%) and poor (<50%).
Group A ( NB – UVB ):
Group B   (PUVA):
Results
No. of 
Patients
Percentage
% reduction in PASI 
score at 16 weeks
Good 11 61 % >96 %
Moderate 5 28 % >72 %
Poor 2 11 % 10-30 %
In group A  -
Out of 20 patients,
 14 patients had good response.
 2 patients moderately responded and 
 3 patients were resistant  to  NB- UVB therapy
 1 patient discontinued therapy.
Results
No. of 
Patients
Percentage
% reduction in PASI 
score at 16 weeks
Good 14 74 % 100 %
Moderate 2 11 % >85 %
Poor response 3 16 % 30-40 %
In group B –
Out of the 20 patients,
 11 patients  responded well
 5   patients responded moderately and 
 2   patients were resistant to therapy,  and  
 2   patients discontinued therapy.    
12)         Adverse effects :  
Adverse effect Group A Group B
Pruritus 1 1
Erythema 1 1
Pigmentation 3 2
Gen weakness 1 0
Initial exacerbation 2 1
Out of the 40 patients, the following adverse effects were noted.
 Exacerbation pruritus in 2 patients,
 Erythema  in 2 patients
 Generalised pigmentation in 5 patients
 Generalised weakness in 1 patient
 Initial exacerbation in 3 patients, which gradually resolved 
after continuation of the therapy.   
DISCUSSION
      Since  the  introduction  of  Narrow  Band-UVB  to  the  field  of 
phototherapy  for  Psoriasis,  many  studies  reported  that  it  is  more 
effective  and  safer  than  PUVA and  has  a  good  effect  on  quality  of  
life.
However  others  recommended  the  superiority  of  PUVA.  On 
the  other  side  some  reports  revealed  that  both  therapies  have  equal 
effect.
To  gain  our  own  experience,  this  study  was  designed  to 
compare  NB-UVB  therapy  to  PUVA  therapy  in  the  management  of 
chronic plaque type psoriasis.
TREATMENT RESPONSE 
We found that  NB-UVB therapy  is  slightly  superior  to  PUVA 
therapy.  The  final  evaluation  involved  comparison  of  both 
treatments  according  to  the  response,  cumulative  dose  and  adverse 
effects.  The  response  of  patients  ranged  from  excellent  (75  %  or 
More decrease  in  PASI score)  to  no response (Fixed or   only Slight 
decrease  in  PASI  score).  Patients  showed  slightly  increased 
response  to  NB-UVB  compared  to  PUVA.  These  results  are 
consistent with some of the studies. 6 2 ,6 3 , 6 4                       
PRETREATMENT PASI 
Group Range Mean SD P
A
(NB-UVB)
21.9 to 59.9 35.01 8.78
0.185
(Not 
Significant)B (PUVA) 17 – 52.2 31.08 9.58
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PRE TREATMENT PASI
PASI AT THE END OF THERAPY 
Group Range Mean SD P
A 0 – 10.5 1.3 3.57 0.0436 
(Significant)B 0 – 11.8 2.99 4.2
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SIDE EFFECTS
In  our  study,  side  effect  like  generalised  pigmentation, 
erythema,  pruritus,  generalised  weakness  and  initial  exacerbation 
were  noted.  No significant  difference in  the  side  effect  between the 
two therapies.
In  our  study,  significant  erythema  is  noted  only  in  two 
patients,  one  patient  in  NB-UVB  and  other  in  PUVA  but  in  many 
other  studies,  common  side  effect  of  UV therapy  is  erythema.  This 
significant  difference is  probably  because,  all  of  our  patients  are  of 
skin type IV and V.
Exacerbated  pruritus  is  noted  in  two  of  our  patients  initially, 
which  subsided  after  continuation  of  therapy.  It  is  assumed  to  be 
related to prostaglandin relies.
Generalised  pigmentation  is  noted  in  three  of  our  patients  on 
NB-UVB  and  two  patients  on  PUVA.  It  shows  an  higher  incidence 
than  in  other  studies,  pigmentation  is  a  common  complication  in 
dark  skinned  individuals. 6 5  This  may  be  a  reason  for  increase 
incidence of pigmentation in our patients. 
Adverse side 
effects
NB-UVB Group PUVA Group
No. % No. %
Erythema 1 5.6 1 5.5
Pruritus 1 5.6 1 5.5
Pigmentation 3 15.7 2 11
Initial 
exacerbation
2 11.1 1 5.3
Gen. weakness 1 5.6 0 0
Total 
complications
8 42.1 5 26.3
No 
complications
11 57.8 14 73.7
‘p’
0.3787
Not significant
ADVERSE SIDE EFFECTS
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TREATMENT RESISTANCE 
Treatment  resistance  is  noted  in  three  of  our  patients  in  NB-
UVB and two patients in PUVA. It  correlates with the long duration 
of  illness and it  has no correlation with PASI score at  the  initiation 
of therapy.
TOTAL CUMULATIVE DOSE          
Mean  cumulative  dose  of  NB-UVB  in  our  study  was  of  27.2 
J/cm2  and  in  PUVA  it  was  223.3  J/cm 2.  Cumulative  dose  is 
significantly  higher  in  patients  in  PUVA therapy when compared to 
NB-UVB,  Which  may  explain  the  carcinogenic  potential  of  PUVA 
when compared to  NB-UVB.
CUMULATIVE DOSE OF NB-UVB AND PUVA THERAPY
 Range
(J/cm2  )
Mean
(J/cm2  )
SD ‘ P ‘
Group A 
(NB-UVB)
12.1 – 84.60 27.2 17.9 0.0001
(SIGNIFICANT)Group B 
(PUVA)
45.5 – 461 223.3 135.5
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CUMULATIVE DOSE OF NB-UVB AND PUVA THERAPY
CONCLUSION
 NB-UVB phototherapy is superior when compared to PUVA in 
the treatment of plaque type psoriasis.  
 The  response  to  therapy  is  better  with  NB-UVB than      with 
PUVA therapy
 The  therapeutic  effect  of  NB-UVB  is  achieved  with 
significantly  lower  cumulative  dose  which  means a  lower  risk 
for  incidence  of  long  term  complication,  with  special 
reference to skin malignancy.
 NB-UVB  is  more  convenient  for  the  patient  and  is  less  time 
consuming.
 No  exogenous  photosensitizer  is  used  NB-UVB  therapy,  thus 
prevents the side effect of psoralen.
 No  need  for  eye  and  skin  protection  after  the  session  in  NB-
UVB phototherapy.
 It  can be used in pregnancy, lactation and it  is useful and well 
tolerated  treatment  for  children,  but  concerns  remain 
regarding its long term side effects.
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PROFORMA
Name                     :
Age / Sex                :  
Case No                  :
Psoriasis Clinic No   :
Marital Status          :
Occupation              :
Address                   :
HISTORY
         Duration                        :      Months/ Yrs
         Itching                          :       Yes/No
         Previous Treatment        :      Topical/ Systemic  
• EXACERBATION WITH   :
Cold Climate 
Sunlight
Infection
Trauma
Drugs
Emotional Factors 
Puberty 
Pregnancy 
Menopause
• Preceeding sore throat -         Yes/No
• Alcohol Intake         -    Yes/No
• Smoking         -          Yes/No
• Systemic illness like Diabetes, Hypertension, Tuberculosis or 
Renal Diseases 
• Pregnancy -        Yes/No
• Lactation -        Yes/No
• Past history of Photosensitivity, Cutaneous Malignancies, or 
Radiotherapy 
• Family history of Psoriasis 
DRUG INTAKE
NAME OF THE DRUG YES NO
DURATION OF 
TREATMENT
YEAR MONTH
Lithium
β  blockers 
Antimalarials
Steroid Withdrawal
Clonidine
Potassium iodine
Amiodarone
Digoxin
Trazadone
Gemfibrozil
Penicillin
Terfenadine
NSAIDs
Natural remedies.
EXAMINATION
        General
Systemic
CVS
RS
Abdomen
CNS
Dermatological  :  
         Morphology of the lesions 
         Sites of involvement
Auspitz Sign : No/Yes
Clinical Type :        -  Chronic Stable Plaque
         -  Scalp
         -  Palmoplantar 
         -  Others-Guttate / Erythrodermic / 
                                -   Unstable / Flexural/ Sebo/Rupioid 
Nail Changes  :   -   None
                              -   Pitting 
                         -  Oycholysis 
                                  -  Subungual  hyperkeratosis 
                              -  Oil Drop Sign
                               -  Splinter Hemorrhages 
                              -  Ridges
                                  -  Yellow discoloration
Joint Involvement : -   None 
                                  -   Classical DIP joint arthritis 
   -   Asymmetric Oligoarthritis
                                  -   Symmetric  Polyarthritis
                                  -   Axial arthritis 
                                  -   Arthritis Mutilans 
Focal Sepsis  :     ENT/ Dental/ Others
Area and severity assessment by PASI scoring:
Erythema/Infiltration/Desquamation Scoring Area Scoring 
0 - Nil 0 – Nil
1 - Mild 1 – 0%-9%
2 - Moderate 2 – 10 % - 29%
3 - Severe 3 – 30 % - 49 %
4 - Very Severe 4 – 50 % - 69 %
5 – 70 % - 89 %
6 – 90 % - 100 %  
PASI      = 0.1 (EH  + IH  + DH) AH  + 0.2 (EU  + IU  + DU) AU
0.3 (ET  + IT  + DT) AT  + 0.4 (EL  + IL  + DL) AL
INVESTIGATION 
Blood Sugar : Urea : Creatinine :
Blood VDRL: HIV:
Ophthalmic Examination 
Date
LFT
SGOT
SGPT
SAP
Total Proteins 
Total 
Bilirubin
Haemogram
TC
DC
Hb
ESR
UV CHART
Date Cycle Dose Duration
Cumulative 
Dose
Side Effects
KEY TO MASTER CHART
P - Pitting
O - Onycholysis
SUH - Subugual Hyperkeratosis
YD - Yellow Discolouration
SE - Side effects
Pi - Generalised pigmentation 
Itc - Itching
Ery - Erythema
Gw            -       Generalised weakness
Ie - Initial Exacerbation
BEFORE TREATMENT
AFTER NB-UVB THERAPY
BEFORE TREATMENT
EXACERBATION AND ERYTHEMA INDUCED BY 
PUVA THERAPY
COMBINED PHOTOTHERAPY UNIT (NB-UVB & PUVA)
BEFORE TREATMENT
AFTER NB-UVB THERAPY
BEFORE TREATMENT
AFTER PUVA THERAPY
BEFORE TREATMENT – PLAQUE TYPE PSORIASIS
IN A 12 YEAR OLD GIRL
AFTER NB-UVB THERAPY

